{
    "clinical_study": {
        "@rank": "36952", 
        "arm_group": [
            {
                "arm_group_label": "PG2", 
                "arm_group_type": "Experimental", 
                "description": "Treatment Group:\nPG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control group:\nPlacebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "PG2 has been approved in Taiwan to treat cancer-related fatigue for advanced cancer\n      patients. The primary objective of this study is to evaluate the efficacy of PG2 on fatigue\n      relief in patients undergoing palliative abdominal surgery for cancer. The secondary\n      endpoints,    including the length of hospital stay, postoperative complications, HRQL,\n      inflammatory biomarkers, the duration of antibiotic therapy, mortality during the hospital\n      stay, weight loss and body composition, will be evaluated among these patients."
        }, 
        "brief_title": "Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Surgery", 
            "Fatigue"
        ], 
        "condition_browse": {
            "mesh_term": "Fatigue"
        }, 
        "detailed_description": {
            "textblock": "This will be a double-blind, randomized, and placebo-controlled study. At least 40 evaluable\n      patients who are scheduled for palliative abdominal surgery for cancer will be randomly\n      assigned to the control or treatment group. Each group will have at least 20 patients and be\n      treated as follows: 1) control group: patients will accept placebo 1 dose a day (POD-1)\n      before surgery and 1 dose a day for 3 days after surgery (POD+0 to POD+2); 2) treatment\n      group: patients will accept PG2 1 dose a day (POD-1) before surgery and 1 dose a day for 3\n      days after surgery (POD+0 to POD+2)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have cancer and are scheduled for palliative abdominal surgery for\n             cancer\n\n          -  Age > 20 years older\n\n          -  Patients who signed the informed consent form\n\n        Exclusion Criteria:\n\n          -  Patients, at screening, has levels greater than 2.5 times the upper limit of normal\n             liver function of alanine aminotransferase or aspartate aminotransferase.\n\n          -  Patients has a severe renal impairment (defined as serum creatinine greater than 2\n             times the upper limit of normal or BUN greater than 2.5 times the upper limit of\n             normal for range); or the subject is on dialysis.\n\n          -  Patients have ongoing infection, respiratory tract dysfunction, cardiac dysfunction\n             or immune disorder that, in the opinion of the investigator, may interfere with\n             conduct of the study.\n\n          -  Patients who are not suitable for undergoing surgery (e.g. congenital hemostatic\n             disorders) by the investigator's judgment.\n\n          -  Patients have enrolled or have not yet completed other investigational drug trials\n             within 1 month before screening.\n\n          -  Female patients are pregnant or breast-feeding.\n\n          -  Patients who require preoperative nutritional support\n\n          -  Patients with serious comorbidities (American Society of Anesthesiologists Risk Class\n             of 4 or 5).\n\n          -  Patients who is unwilling or unable to answer the quality of life questionnaires i.e.\n             the BFI-T and EORTC QLQ-C30."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077621", 
            "org_study_id": "PH-CP020"
        }, 
        "intervention": [
            {
                "arm_group_label": "PG2", 
                "description": "Powder for Injection, 500 mg PG2/500 ml normal saline", 
                "intervention_name": "PG2", 
                "intervention_type": "Drug", 
                "other_name": "PG2 injection 500mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "500 mL normal saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "cancer-related fatigue", 
            "Palliative Abdominal Surgery", 
            "HRQL"
        ], 
        "lastchanged_date": "March 2, 2014", 
        "location": {
            "contact": {
                "email": "kptkptkpt@yahoo.com.tw", 
                "last_name": "Jin-Ming Wu, M.D.", 
                "phone": "886-223123456", 
                "phone_ext": "65281"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "100"
                }, 
                "name": "National Taiwan University Hospital"
            }, 
            "investigator": {
                "last_name": "Jin-Ming Wu, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer", 
        "overall_contact": {
            "email": "kptkptkpt@yahoo.com.tw", 
            "last_name": "Jin-Ming Wu, MD", 
            "phone": "886-223123456", 
            "phone_ext": "65281"
        }, 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital", 
            "last_name": "Jin-Ming Wu, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "qustionnaires", 
            "measure": "change from baseline fatigue status", 
            "safety_issue": "No", 
            "time_frame": "a day before surgery and day 1,2,7,28,56,84 after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Length of hospital stay", 
                "safety_issue": "No", 
                "time_frame": "13 weeks"
            }, 
            {
                "description": "patients were observed for surgical and nonsurgical complication", 
                "measure": "Postoperative complications", 
                "safety_issue": "No", 
                "time_frame": "13 weeks"
            }, 
            {
                "measure": "Health-related Quality of Life (HRQL)", 
                "safety_issue": "No", 
                "time_frame": "a day before surgery and  for day 7,28,56,84 after surgery"
            }, 
            {
                "measure": "Inflammatory biomarkers: Serum IFN-r, IL-1b, IL-4, IL-6, IL-10 and TNF-a", 
                "safety_issue": "No", 
                "time_frame": "Before operation and on day 1, and day 7 after operation"
            }, 
            {
                "measure": "The duration of antibiotic therapy", 
                "safety_issue": "No", 
                "time_frame": "13 weeks"
            }, 
            {
                "measure": "Mortality during the hospital stay", 
                "safety_issue": "No", 
                "time_frame": "13 weeks"
            }, 
            {
                "description": "patients will be measured during follow-up period", 
                "measure": "Weight loss", 
                "safety_issue": "No", 
                "time_frame": "13 weeks"
            }, 
            {
                "description": "such as protein, mineral, body fat mass", 
                "measure": "Body composition", 
                "safety_issue": "No", 
                "time_frame": "a day before surgery and for day 28 after surgery"
            }
        ], 
        "source": "PhytoHealth Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PhytoHealth Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}